Wigginton Jon Marc
Sr VP, Clinical Dev. & CMO at MGNX
- Sold, on record
- $3.3M
- Dollars the filings state
- Form 4 sales
- 16
- Latest Jan 17, 2018
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- MGNXMACROGENICS INCSr VP, Clinical Dev. & CMO
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale MGNXUnusualJul 1, 2016 2016
Sold 5,000 shares at $27.22 ($136k)
Wigginton Jon Marc, Sr VP Clinical Dev & CMO
Sold 100% of holdings ($136k position)0 shares left1x usual sizeFiling
- 2 Form 4 sale MGNXUnusualAug 1, 2016 +31 days
Sold 20,000 shares at $30.78 ($616k)
Wigginton Jon Marc, Sr VP Clinical Dev & CMO
Sold 100% of holdings ($616k position)0 shares left4x usual sizeFiling
- 3 Form 4 sale MGNXUnusualOct 3, 2016 +63 days
Sold 10,000 shares at $29.34 ($293k)
Wigginton Jon Marc, Sr VP, Clinical Dev. & CMO
Sold 100% of holdings ($293k position)0 shares left2x usual sizeFiling
- 4 Form 4 sale MGNXUnusualApr 19, 2017 +198 days
Sold 15,000 shares at $20.00 ($300k)
Wigginton Jon Marc, Sr VP, Clinical Dev. & CMO
Sold 33.3% of holdings ($900k position)30,000 shares left1.5x usual sizeFiling
- 5 Form 4 sale MGNXPlan not statedJun 5, 2017 +47 days
Sold 5,000 shares at $20.00 ($100k)
Wigginton Jon Marc, Sr VP, Clinical Dev. & CMO
Sold 14.3% of holdings ($700k position)30,000 shares left0.5x usual sizeFiling
- 6 Form 4 sale MGNXUnusualOct 25, 2017 +142 days
Sold 10,000 shares at $20.00 ($200k)
Wigginton Jon Marc, Sr VP, Clinical Dev. & CMO
Sold 25% of holdings ($800k position)30,000 shares left1x usual sizeFiling
- 7 Form 4 sale MGNXPlan not statedNov 21, 2017 +27 days
Sold 5,000 shares at $20.00 ($100k)
Wigginton Jon Marc, Sr VP, Clinical Dev. & CMO
Sold 14.3% of holdings ($700k position)30,000 shares left0.5x usual sizeFiling
- 8 Form 4 sale MGNXPlan not statedJan 17, 2018 +57 days
Sold 5,000 shares at $20.00 ($100k)
Wigginton Jon Marc, Sr VP, Clinical Dev. & CMO
Sold 14.3% of holdings ($700k position)30,000 shares left0.5x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (16)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jan 17, 2018 | Jan 18, 2018 | MGNX | Sr VP, Clinical Dev. & CMO | Form 4 sale | 5,000 | $100k | 14.3% | Plan not stated | SEC |
| Nov 21, 2017 | Nov 21, 2017 | MGNX | Sr VP, Clinical Dev. & CMO | Form 4 sale | 5,000 | $100k | 14.3% | Plan not stated | SEC |
| Oct 25, 2017 | Oct 26, 2017 | MGNX | Sr VP, Clinical Dev. & CMO | Form 4 sale | 10,000 | $200k | 25.0% | Unusual | SEC |
| Jun 5, 2017 | Jun 6, 2017 | MGNX | Sr VP, Clinical Dev. & CMO | Form 4 sale | 5,000 | $100k | 14.3% | Plan not stated | SEC |
| Apr 19, 2017 | Apr 20, 2017 | MGNX | Sr VP, Clinical Dev. & CMO | Form 4 sale | 15,000 | $300k | 33.3% | Unusual | SEC |
| Oct 3, 2016 | Oct 5, 2016 | MGNX | Sr VP, Clinical Dev. & CMO | Form 4 sale | 10,000 | $293k | 100.0% | Unusual | SEC |
| Aug 1, 2016 | Aug 3, 2016 | MGNX | Sr VP Clinical Dev & CMO | Form 4 sale | 20,000 | $616k | 100.0% | Unusual | SEC |
| Jul 1, 2016 | Jul 6, 2016 | MGNX | Sr VP Clinical Dev & CMO | Form 4 sale | 5,000 | $136k | 100.0% | Unusual | SEC |
| Jan 4, 2016 | Jan 6, 2016 | MGNX | Sr VP, Clinical | Form 4 sale | 10,000 | $296k | 100.0% | Unusual | SEC |
| Oct 1, 2015 | Oct 2, 2015 | MGNX | Sr VP, Clinical | Form 4 sale | 5,000 | $106k | 100.0% | Unusual | SEC |
| Aug 3, 2015 | Aug 3, 2015 | MGNX | Sr VP, Clinical | Form 4 sale | 10,000 | $372k | 100.0% | Unusual | SEC |
| Jul 1, 2015 | Jul 1, 2015 | MGNX | Sr VP, Clinical | Form 4 sale | 5,000 | $186k | 100.0% | Unusual | SEC |
| Apr 1, 2015 | Apr 3, 2015 | MGNX | Sr VP, Clinical | Form 4 sale | 5,000 | $154k | 100.0% | Unusual | SEC |
| Feb 2, 2015 | Feb 3, 2015 | MGNX | Sr VP, Clinical | Form 4 sale | 5,000 | $155k | 100.0% | Unusual | SEC |
| Oct 1, 2014 | Oct 2, 2014 | MGNX | Sr V.P., Clinical | Form 4 sale | 5,000 | $102k | 100.0% | Unusual | SEC |
| Aug 18, 2014 | Aug 19, 2014 | MGNX | Senior VP, Clinical Dev. | Form 4 sale | 5,000 | $103k | 100.0% | Unusual | SEC |